(BMS) June 17, 2018 - Primary endpoint of progression-free survival met for the combination of Empliciti plus pomalidomide and low-dose dexamethasone; data will be presented for the first time in late-breaking oral session during the 23rd Congress of the European Hematology Association.

(MedCity News) June 7, 2018 - Although bluebird bio’s CAR-T cell therapy for multiple myeloma is already in a registration-directed clinical trial, Janssen sees plenty of room to muscle in as well.